HER2 fluorescence in situ hybridization groups 2-4 breast cancers classified as positive after targeted recounts following equivocal (2+) immunohistochemistry
American Journal of Clinical Pathology · 2025
DOI: 10.1093/ajcp/aqaf006 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2025. Verfasst von Diane Wilcock und 13 weiteren Autor:innen. Beteiligte Einrichtung: ARUP Laboratories, Salt Lake City, Utah, US. Hauptthemen laut MEDLINE: Breast Neoplasms, In Situ Hybridization, Fluorescence, Erb-b2 Receptor Tyrosine Kinases, Biomarkers, Tumor. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Objectives
To investigate the correlation between the extent of (percentage of tumor cells) immunohistochemistry (IHC) staining and final human epidermal growth factor receptor 2 (HER2)–positive result in fluorescence in situ hybridization (FISH) groups 2 to 4 with equivocal (2+) IHC requiring second, blinded FISH evaluation.
Methods
Breast cancer cases submitted for HER2 FISH testing with group 2 to 4 results were included.
Results
Of the 2548 cases with HER2 FISH groups 2 to 4 that had HER2 IHC performed, 1104 (43.3%) (76/182 [41.8%] of group 2, 94/161 [58.4%] of group 3, 934/2205 [42.4%] of group 4) had equivocal (2+) IHC. After second blinded, IHC-guided recounts, 217 of 1104 (19.7%) (17/76 [22.4%], 75/94 [79.8%], 125/934 [13.4%] of FISH groups 2, 3, 4 with IHC 2+, respectively) had final HER2-positive status. Only 13 of 217 (6%) of the cases with HER2-positive status had more than 50% circumferential staining of the tumor targeted for rescoring.
Conclusions
In over 90% of HER2 FISH group 2 to 4 breast cancers with equivocal (2+) IHC followed by targeted, blinded second FISH evaluation and final HER2-positive result, the amplified population of tumor cells was limited (<50%). Current guidelines recommend cancers having 10% to 50% of the subpopulation with amplified cells classified as having genetic heterogeneity (GH), which have a poor response to targeted therapies. Identifying these tumors as having GH and/or repeat testing may be recommended.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ARUP Laboratories, Salt Lake City, Utah, US.
- Department of Pathology, University of California-San Francisco, San Francisco, California, US.
- Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US.
Zitieren
APA
Wilcock, D., Sirohi, D., Coleman, J. F., Adelhardt, P., Kim, J. T., Albertson, D., Affolter, K., Beech, C., Jedrzkiewicz, J., Ruano, A. L., Cleary, A. S., Mahlow, J., Balatico, M., & Gulbahce, H. E. (2025). HER2 fluorescence in situ hybridization groups 2-4 breast cancers classified as positive after targeted recounts following equivocal (2+) immunohistochemistry. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqaf006
Vancouver
Wilcock D, Sirohi D, Coleman JF, Adelhardt P, Kim JT, Albertson D, et al. HER2 fluorescence in situ hybridization groups 2-4 breast cancers classified as positive after targeted recounts following equivocal (2+) immunohistochemistry. American Journal of Clinical Pathology. 2025. doi:10.1093/ajcp/aqaf006
BibTeX
@article{Wilcock2025,
author = {Wilcock, Diane and Sirohi, Deepika and Coleman, Joshua F and Adelhardt, Parisa and Kim, Jong Taek and Albertson, Daniel and Affolter, Kajsa and Beech, Cameron and Jedrzkiewicz, Jolanta and Ruano, Ana L and Cleary, Allison S and Mahlow, Jonathan and Balatico, Michael and Gulbahce, H Evin},
title = {HER2 fluorescence in situ hybridization groups 2-4 breast cancers classified as positive after targeted recounts following equivocal (2+) immunohistochemistry},
journal = {American Journal of Clinical Pathology},
year = {2025},
doi = {10.1093/ajcp/aqaf006}
}
EUVIMED